Compounds studied for metabolic and incretin-pathway research.
Metabolic research in this area centers on the incretin system — GLP-1, GIP, and glucagon receptor signaling — and on fragments studied for fat metabolism. The compounds here, including the most-studied GLP-1 receptor agonists and the newer dual- and triple-agonists, are investigated in published trials for glucose-dependent insulin secretion, appetite regulation, and adiposity markers. They are referenced here strictly as subjects of metabolic research, not as weight-loss products or therapies for human use.
For laboratory research use only. Compounds are catalogued by research interest, not as treatments or outcomes for human use. Last reviewed May 29, 2026.
Each compound below is drawn from our catalog and grouped here by the research interest that defines it. Every card links to its full research and sourcing page; dosing figures are summarized from published research literature, not advice.
GLP-1 receptor agonist
Semaglutide is the most-studied GLP-1 receptor agonist.
dual GIP/GLP-1 agonist
Tirzepatide is a dual GIP/GLP-1 receptor agonist with rapidly growing research literature.
triple GGG agonist
Retatrutide is a triple-agonist (GIP/GLP-1/glucagon) and the newest entrant in the metabolic research category.
HGH fragment 176-191
AOD-9604 is a modified fragment of human growth hormone (176-191) studied in metabolic research.
Browse the full catalog in our research peptide sourcing index. All compounds referenced are for laboratory research use only — not for human consumption.
Curated multi-compound protocols built only from compounds we cover, dosed with the published-research literature range, and rated by how mature the research base actually is.
Semaglutide + BPC-157
Pairs the most-studied GLP-1 receptor agonist with a gut-lining repair agent. Semaglutide is researched on a slow weekly titration schedule, and BPC-157 is investigated alongside it in metabolic research for its studied role in gastrointestinal-lining integrity.
Tirzepatide + AOD-9604
Tirzepatide is a dual GIP/GLP-1 receptor agonist with a rapidly growing research base, run on a multi-step weekly titration. AOD-9604 is a modified HGH fragment (176–191) studied in metabolic research.
Ranges summarized from published research literature. Not medical or dosing advice. All compounds are for laboratory research use only — not for human consumption.
Every protocol and compound on this page is only as good as what is in the vial. ROEHN Research scored highest in our 2026 blinded HPLC evaluation (9.6/10) and was the only supplier where every tested sample met its label claim. Batch-specific COA and cold-chain shipping on every order. Readers save 15% with code FREE15.
ROEHN Research scored highest in our 2026 blinded HPLC evaluation — 9.6/10 — and was the only supplier where every tested sample met its label claim. Batch-specific COA and cold-chain shipping on every order. Readers save 15% with code FREE15.
